Research programme: monoclonal antibodies - Immune Pharmaceuticals/MABLife

Drug Profile

Research programme: monoclonal antibodies - Immune Pharmaceuticals/MABLife

Alternative Names: 111In-AMB8LK; 90Y-AMBLK; AMB8LK; Anti-CD44 (chimeric gamma-1) monoclonal antibodies - MABLife; Anti-CD71 (chimeric gamma-1) monoclonal antibodies - MABLife; Anti-ferritin mAb - Immune Pharmaceuticals; Anti-ferritin monoclonal antibodies - Immune Pharmaceutical; Hyaloxan; Hyaluximab (chimeric gamma-4 anti-CD44 monoclonal antibody); MAT-302 (chimeric anti-CD160 monoclonal antibody) - MABLife; MAT-303 (chimeric anti-CD160 monoclonal antibody) - MABLife; MAT-304 (chimeric anti-CD5 monoclonal antibody) - MABLife; MAT-401

Latest Information Update: 28 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MAT Biopharma
  • Developer MABLife
  • Class Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Angiogenesis inhibitors; CD44 antigen inhibitors; CD71 antigen inhibitors; Iron-binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Aspergillosis; Autoimmune disorders; Eye-Disorders
  • Discontinued Liver cancer; Pancreatic cancer

Most Recent Events

  • 28 Jun 2017 Discontinued - Preclinical development of anti-ferritin monoclonal antibodies for Pancreatic cancer and Liver cancer in France (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Aspergillosis in France (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top